|
1.
|
|
10 p, 2.6 MB |
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
/
García-Prieto, Carlos A (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Villanueva, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno-Costa, Alberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
González-Navarro, Europa Azucena (Department of Immunology. Hospital Clinic) ;
Juan, Manuel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Urbano-Ispizua, Álvaro (Department of Hematology. University of Barcelona) ;
Delgado, Julia (Centro de Investigación Biomedica en Red de Cancer) ;
Ortiz-Maldonado, Valetín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Del Bufalo, Francesca (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Locatelli, Franco (Sapienza University of Rome) ;
Quintarelli, Concetta (Department of Clinical Medicine and Surgery. University of Naples Federico II) ;
Sinibaldi, Matilde (Department of Paediatric Haematology and Oncology. Bambino Gesù Children's Hospital) ;
Soler, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Castro De Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferrer, Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urdinguio, Rocío G. (Universidad de Oviedo) ;
Fernandez, A.F. (Universidad de Oviedo) ;
Fraga, Mario F. (Universidad de Oviedo) ;
Bar, Diana (The Edmond and Lily Safra Children's Hospital) ;
Meir, Agustín (The Edmond and Lily Safra Children's Hospital) ;
Itzhaki, Orit (Ella Lemelbaum Institute for Immuno Oncology) ;
Besser, MichalJ. (Tel Aviv University) ;
Avigdor, Abraham (Sheba Medical Center) ;
Jacoby, Elad (Tel Aviv University) ;
Esteller, Manel (Universitat de Barcelona. Departament de Ciències Fisiològiques)
Background: Chimeric antigen receptor (CAR) T cells directed against CD19 (CART19) are effective in B-cell malignancies, but little is known about the molecular factors predicting clinical outcome of CART19 therapy. [...]
2022 -  10.1093/jnci/djab194
Journal of the National Cancer Institute, Vol. 114 Núm. 3 (january 2022) , p. 436-445
|
|
|
2.
|
|
22 p, 2.9 MB |
Advancing CART therapy for acute myeloid leukemia : recent breakthroughs and strategies for future development
/
Pérez-Amill, Lorena (Department of Immunology. Centre de Diagnòstic Biomèdic (CDB). Hospital Clínic de Barcelona) ;
Bataller, Alex (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Delgado, Julio (Universitat de Barcelona) ;
Esteve, Jordi (Universitat de Barcelona) ;
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Klein-González, Nelia (Hospital Clínic i Provincial de Barcelona)
Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid leukemia (AML) on the basis of the results obtained for other haematological malignancies and the need of new treatments for relapsed and refractory AML. [...]
2023 - 10.3389/fimmu.2023.1260470
Frontiers in immunology, Vol. 14 (2023) , p. 1260470
|
|
|
3.
|
|
16 p, 3.4 MB |
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors
/
Dragon, Anna Christina (Hannover Medical School) ;
Beermann, Luca Marie (Hannover Medical School) ;
Umland, Melina (Hannover Medical School) ;
Bonifacius, Agnes (Hannover Medical School) ;
Malinconico, Chiara (Hannover Medical School) ;
Ruhl, Louisa (Hannover Medical School) ;
Kehler, Patrik (Glycotope GmbH) ;
Gellert, Johanna (Glycotope GmbH) ;
Weiß, Lisa (Glycotope GmbH) ;
Mayer-Hain, Sarah (Glycotope GmbH) ;
Zimmermann, Katharina (Hannover Medical School) ;
Riese, Sebastian (Hannover Medical School) ;
Thol, F. (Department of Hematology. Hannover Medical School) ;
Beutel, Gernot (Hannover Medical School) ;
Maecker-Kolhoff, B. (Department of Pediatric Hematology and Oncology. Hannover Medical School) ;
Yamamoto, Felicitas (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blasczyk, Rainer (Hannover Medical School) ;
Schambach, Axel (Hannover Medical School) ;
Hust, Michael (Department of Medical Biotechnology. Technical University of Braunschweig) ;
Hudecek, Michael (Department of Internal Medicine II. University Hospital of Würzburg) ;
Eiz-Vesper, Britta (Hannover Medical School) ;
Universitat Autònoma de Barcelona
Introduction: Chimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy cells, since "on-target/off-tumor" cytotoxicity is usually intolerable. [...]
2023 - 10.3389/fimmu.2023.1219165
Frontiers in immunology, Vol. 14 (2023) , p. 1219165
|
|
|
4.
|
|
12 p, 2.4 MB |
Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
/
Page, Elizabeth C. (Institute of Cancer Research) ;
Bancroft, Elizabeth K. (Royal Marsden NHS Foundation Trust) ;
Brook, Mark N. (Institute of Cancer Research) ;
Assel, Melissa (Memorial Sloan Kettering Cancer Center) ;
Hassan Al Battat, Mona (Lund University) ;
Thomas, Sarah (Royal Marsden NHS Foundation Trust) ;
Taylor, Natalie (Royal Marsden NHS Foundation Trust) ;
Chamberlain, Anthony (Institute of Cancer Research) ;
Pope, Jennifer (Institute of Cancer Research) ;
Raghallaigh, Holly Ni (Institute of Cancer Research) ;
Evans, D.Gareth (Central Manchester University Hospitals NHS Foundation Trust) ;
Rothwell, Jeanette (Central Manchester University Hospitals NHS Foundation Trust) ;
Maehle, Lovise (Oslo University Hospital (Oslo, Noruega)) ;
Grindedal, Eli Marie (Oslo University Hospital (Oslo, Noruega)) ;
James, Paul (The Royal Melbourne Hospital) ;
Mascarenhas, Lyon (Peter MacCallum Cancer Centre) ;
McKinley, Joanne (Peter MacCallum Cancer Centre) ;
Side, Lucy (Princess Anne Hospital) ;
Thomas, Tessy (Princess Anne Hospital) ;
van Asperen, Christi (Leiden University Medical Center) ;
Vasen, Hans (The Foundation for the Detection of Hereditary Cancer) ;
Kiemeney, Lambertus A. (Radboud University Medical Center) ;
Ringelberg, Janneke (The Foundation for the Detection of Hereditary Cancer) ;
Jensen, Thomas Dyrso. (Vejle Hospital) ;
Osther, Palle J.S. (Vejle Hospital) ;
Helfand, Brian T. (NorthShore University HealthSystem) ;
Genova, Elena (NorthShore University HealthSystem) ;
Oldenburg, Rogier A. (Erasmus University Medical Center) ;
Cybulski, Cezary (Pomeranian Medical University in Szczecin) ;
Wokolorczyk, Dominika (Pomeranian Medical University in Szczecin) ;
Ong, Kai-Ren (Birmingham Women's Hospital) ;
Huber, Camilla (Birmingham Women's Hospital) ;
Lam, Jimmy (Bedford Park) ;
Taylor, Louise (Daw Park) ;
Salinas, Monica (Hospital Universitari de Bellvitge) ;
Feliubadaló, Lidia (Hospital Universitari de Bellvitge) ;
Oosterwijk, Jan C. (University of Groningen) ;
van Zelst-Stams, Wendy (Radboud University Medical Center) ;
Cook, Jackie (Sheffield Children's Hospital (Sheffield, Regne Unit)) ;
Rosario, Derek J. (Royal Hallamshire Hospital) ;
Domchek, Susan (Basser Research Center. University of Pennsylvania) ;
Powers, Jacquelyn (University of Pennsylvania) ;
Buys, Saundra (University of Utah) ;
O'Toole, Karen (University of Utah) ;
Ausems, Margreet G. E. M (University Medical Centre) ;
Schmutzler, Rita K. (University Hospital Cologne) ;
Rhiem, Kerstin (University Hospital Cologne) ;
Izatt, Louise (Guy's and St Thomas' NHS Foundation Trust) ;
Tripathi, Vishakha (Guy's and St Thomas' NHS Foundation Trust) ;
Teixeira, Manuel R. (Porto University) ;
Cardoso, Marta (Portuguese Oncology Institute (IPO Porto)) ;
Foulkes, William D. (McGill University, Departments of Human Genetics and Oncology) ;
Aprikian, Armen (Research Institute of McGill University Health Centre) ;
van Randeraad, Heleen (The Foundation for the Detection of Hereditary Cancer) ;
Davidson, Rosemarie (Queen Elizabeth University Hospital) ;
Longmuir, Mark (Queen Elizabeth University Hospital) ;
Ruijs, Marielle W.G. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Helderman van den Enden, Apollonia T.J.M. (Maastricht University Medical Center) ;
Adank, Muriel (Amsterdam UMC) ;
Williams, Rachel (Prince of Wales Hospital (Australia)) ;
Andrews, Lesley (Prince of Wales Hospital (Australia)) ;
Murphy, Declan G. (Peter MacCallum Cancer Centre) ;
Halliday, Dorothy (Oxford Centre for Genomic Medicine) ;
Walker, Lisa (Oxford Centre for Genomic Medicine) ;
Liljegren, Annelie (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Carlsson, Stefan (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Azzabi, Ashraf (Newcastle upon Tyne Hospitals) ;
Jobson, Irene (Newcastle upon Tyne Hospitals) ;
Morton, Catherine (The Royal Melbourne Hospital) ;
Shackleton, Kylie (The Royal Melbourne Hospital) ;
Snape, Katie (St George's Hospital) ;
Hanson, Helen (St George's Hospital) ;
Harris, Marion (Monash Health) ;
Tischkowitz, Marc (University of Cambridge) ;
Taylor, Amy (Cambridge University Hospitals NHS Trust) ;
Kirk, Judy (Sydney Medical School) ;
Susman, Rachel (Royal Brisbane & Women's Hospital) ;
Chen-Shtoyerman, Rakefet (Kaplan Medical Center) ;
Spigelman, Allan (The Kinghorn Cancer Centre. St Vincent's Hospital) ;
Pachter, Nicholas (University of Western Australia) ;
Ahmed, Munaza (NE Thames Regional Genetics Service) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
Zgajnar, Janez (Institute of Oncology) ;
Brewer, Carole (Royal Devon and Exeter Hospital) ;
Gadea, Neus (Hospital Universitari Vall d'Hebron) ;
Brady, Angela F. (London North West University Healthcare NHS Trust) ;
van Os, Theo (Academic Medical Center) ;
Gallagher, David (St James's Hospital) ;
Johannsson, Oskar (Landspitali University Hospital (Reykjavík, Islàndia)) ;
Donaldson, Alan (St Michael's Hospital) ;
Barwell, Julian (University Hospitals Leicester) ;
Nicolai, Nicola (Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Friedman, Eitan (Chaim Shema Medical Center) ;
Obeid, Elias (Fox Chase Cancer Center) ;
Greenhalgh, Lynn (Liverpool Women's Hospital) ;
Murthy, Vedana (Tata Memorial Centre) ;
Copakova, Lucia (National Cancer Institute) ;
Saya, Sibel (Institute of Cancer Research) ;
McGrath, John (University of Exeter Medical School) ;
Cooke, Peter (New Cross Hospital) ;
Rønlund, Karina (Vejle Hospital) ;
Richardson, Kate (Peter MacCallum Cancer Centre) ;
Henderson, Alex (West Cumberland Infirmary) ;
Teo, Soo H. (Subang Jaya Medical Centre) ;
Arun, Banu (The University of Texas) ;
Kast, Karin (Technische Universität Dresden) ;
Dias, Alexander (Instituto Nacional de Cancer Jose de Alencar Gomes da Silva (INCA)) ;
Aaronson, Neil K (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
Ardern-Jones, Audrey (Royal Marsden NHS Foundation Trust) ;
Bangma, Chris H. (Erasmus University Medical Center) ;
Castro, Elena (Centro Nacional de Investigaciones Oncológicas) ;
Dearnaley, David (The Institute of Cancer Research. Royal Marsden NHS Foundation Trust (Londres, Regne Unit)) ;
Eccles, Diana M. (The University of Southampton Medical School) ;
Tricker, Karen (Central Manchester University Hospitals NHS Foundation Trust) ;
Eyfjord, Jorunn (University of Iceland) ;
Falconer, Alison (Imperial College Healthcare NHS Trust) ;
Foster, Christopher (HCA Pathology Laboratories) ;
Gronberg, Henrik (University Hospital) ;
Hamdy, Freddie C. (University of Oxford) ;
Stefansdottir, Vigdis (Landspitali University Hospital (Reykjavík, Islàndia)) ;
Khoo, Vincent (The University of Melbourne) ;
Lindeman, Geoffrey J. (The Walter and Eliza Hall Institute of Medical Research) ;
Lubinski, Jan (Pomeranian Medical University in Szczecin) ;
Axcrona, Karol (Akershus University Hospital) ;
Mikropoulos, Christos (Medway Hospital) ;
Mitra, Anita (University College London Hospitals NHS Foundation Trust) ;
Moynihan, Clare (Institute of Cancer Research) ;
Rennert, Gadi (Carmel Medical Center) ;
Suri, Mohnish (Nottingham City Hospital) ;
Wilson, Penny (Innovate UK. Polaris House) ;
Dudderidge, Tim (University Hospital Southampton) ;
Offman, Judith (King's College London) ;
Kote-Jarai, Zsofia (Institute of Cancer Research) ;
Vickers, Andrew (Memorial Sloan Kettering Cancer Center) ;
Lilja, Hans (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Eeles, Rosalind A. (Royal Marsden NHS Foundation Trust) ;
Universitat Autònoma de Barcelona
Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. [...]
2019 - 10.1016/j.eururo.2019.08.019
European Urology, Vol. 76 Núm. 6 (december 2019) , p. 831-842
|
|
|
5.
|
|
11 p, 2.0 MB |
Development of a Novel Anti-CD19 Chimeric Antigen Receptor : A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
/
Castella, Maria (Hospital Clínic i Provincial de Barcelona) ;
Boronat, Anna (Hospital Clínic i Provincial de Barcelona) ;
Martín-Ibáñez, Raquel (Universitat de Barcelona) ;
Rodríguez, Vanina (Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS) ;
Suñé, Guillermo (Hospital Clínic i Provincial de Barcelona) ;
Caballero, Miguel (Hospital Clínic i Provincial de Barcelona) ;
Marzal, Berta (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Amill, Lorena (Hospital Clínic i Provincial de Barcelona) ;
Martín-Antonio, B. (Hospital Clínic i Provincial de Barcelona) ;
Castaño Cardoso, Julio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Balagué, Olga (Hospital Clínic i Provincial de Barcelona) ;
González-Navarro, Europa Azucena (Hospital Clínic i Provincial de Barcelona) ;
Serra-Pages, Carles (Hospital Clínic i Provincial de Barcelona) ;
Engel, Pablo (Hospital Clínic i Provincial de Barcelona) ;
Vilella, Ramon (Hospital Clínic i Provincial de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Ortiz-Maldonado, Valentín (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Tabera, Jaime (Institut d'Investigació Biomèdica Sant Pau) ;
Canals, Josep M. (Universitat de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Baumann, Tycho (Hospital Clínic i Provincial de Barcelona) ;
Vilarrodona, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Trias, Esteve (Hospital Clínic i Provincial de Barcelona) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Menéndez Bujan, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urbano-Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Yagüe, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Pérez-Galán, Patricia (Centro de Investigación Biomédica en Red de Cáncer) ;
Rives, Susana (Institut de Recerca Sant Joan de Déu) ;
Delgado, Julio (Hospital Clínic i Provincial de Barcelona) ;
Juan, Manel (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). [...]
2019 - 10.1016/j.omtm.2018.11.010
Molecular Therapy. Methods & Clinical Development, Vol. 12 (15 2019) , p. 134-144
|
|
|
6.
|
|
9 p, 488.9 KB |
PROSHADE Protocol : Designing and Evaluating a Decision Aid for Promoting Shared Decision Making in Opportunistic Screening for Prostate Cancer: A Mix-Method Study
/
Lumbreras, Blanca (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Parker, Lucy Anne (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública) ;
Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Mira-Bernabeu, Javier (Hospital Universitario de San Juan. Servicio de Medicina Preventiva) ;
Gómez-Pérez, Luis (Hospital Universitario de San Juan. Servicio de Urología) ;
Caballero-Romeu, Juan Pablo (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Pertusa-Martínez, Salvador (Centro de Salud Cabo Huertas) ;
Cebrián-Cuenca, Ana M (Centro de Salud Cartagena Casco) ;
Moral Peláez, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
López-Garrigós, Maite (Hospital Universitario de San Juan. Laboratorio Clínico) ;
Canelo Aybar, Carlos Gilberto (Institut d'Investigació Biomèdica Sant Pau) ;
Ronda, Elena (Universitat d'Alacant. Grup de Recerca en Salut Pública) ;
Guilabert, Mercedes (Universidad Miguel Hernández. Departamento de Psicología de la Salud) ;
Prieto-González, Antonio (Asociación de Cáncer de Próstata) ;
Hernández-Aguado, Ildefonso (Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública)
Background: Opportunistic prostate-specific antigen (PSA) screening may reduce prostate cancer mortality risk but is associated with false positive results, biopsy complications and overdiagnosis. Although different organisations have emphasised the importance of shared decision making (SDM) to assist men in deciding whether to undergo prostate cancer screening, recent evaluations show that the available decision aids fail to facilitate SDM, mainly because they do not consider the patients' perspective in their design. [...]
2022 - 10.3390/ijerph19158904
International journal of environmental research and public health, Vol. 19 Núm. 15 (august 2022) , p. 8904
|
|
|
7.
|
|
22 p, 3.7 MB |
Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
/
Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ;
Borque-Fernando, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Triquell, Marina (Hospital Universitari Vall d'Hebron) ;
Celma, Ana (Hospital Universitari Vall d'Hebron) ;
Regis, Lucas (Hospital Universitari Vall d'Hebron) ;
Mast, Richard (Hospital Universitari Vall d'Hebron) ;
de Torres, Inés M. (Hospital Universitari Vall d'Hebron) ;
Semidey, María E. (Hospital Universitari Vall d'Hebron) ;
Abascal, Jose Maria (Parc de Salut MAR de Barcelona) ;
Servian, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fàbrega-Santamaria, Anna (Hospital Universitari Vall d'Hebron) ;
Planas, Jacques (Hospital Universitari Vall d'Hebron) ;
Esteban, Luis M (Universidad de Zaragoza) ;
Trilla Herrera, Enrique (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Magnetic resonance imaging (MRI)-associated prostate-specific antigen density (mPSAD) and MRI predictive models have been proposed for improving the selection of candidates for prostate biopsy among men with suspected prostate cancer (PCa). [...]
2022 - 10.3390/cancers14102374
Cancers, Vol. 14 (may 2022)
|
|
|
8.
|
|
7 p, 870.6 KB |
Feasibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen self-testing in school and summer camp attendees
/
Colom Cadena, Andreu (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-Riveros, Héctor (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bordas, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Alonso García, Lucía (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Montoro-Fernández, Marcos (Catalunya. Generalitat) ;
Romano-deGea, Pol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vidal-Alaball, Josep (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Solà-Segura, Elisabet (Institut Català de la Salut) ;
Llibre, Josep M.. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Revollo, Boris (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Casabona-Barbarà, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Agustí, Cristina (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
SARS-CoV-2 screening is one of the pillars of non-pharmaceutical preventive strategies to early identify and isolate infected individuals and therefore decrease community incidence. We assessed the feasibility of severe acute respiratory syndrome coronavirus 2 self-testing with antigen-detecting rapid diagnostic tests in attendees of educational settings. [...]
2023 - 10.3389/fped.2022.975454
Frontiers in Pediatrics, Vol. 10 (january 2023)
|
|
|
9.
|
|
|
10.
|
|
13 p, 865.1 KB |
A rapid calprotectin test for the diagnosis of pleural effusion
/
Casado-Rey, P. (Hospital Álvaro Cunqueiro (Vigo)) ;
Vázquez-Iglesias, L. (Instituto de Investigación Sanitaria Galicia Sur) ;
Botana-Rial, M. (Instituto de Investigación Sanitaria Galicia Sur) ;
Andrade-Olivié, M.A. (Hospital Álvaro Cunqueiro (Vigo)) ;
Ferreiro-Fernández, L. (Instituto de Investigación Sanitaria de Santiago (IDIS)) ;
José Capilla, E.S. (Clinical Chemistry Department. University Hospital Complex of Santiago. EOXI) ;
Núñez-Ares, Ana (Complejo Hospitalario Universitario de Albacete) ;
de Miguel, E.B. (Pulmonary Department. University Hospital Complex of León) ;
Pajares Ruiz, Virginia (Institut d'Investigació Biomèdica Sant Pau) ;
Fernández-Villar, A. (Instituto de Investigación Sanitaria Galicia Sur)
In previous studies, measuring the levels of calprotectin in patients with pleural effusion (PE) was an exceptionally accurate way to predict malignancy. Here, we evaluated a rapid method for the measurement of calprotectin levels as a useful parameter in the diagnosis of malignant pleural effusion (MPE) in order to minimise invasive diagnostic tests. [...]
2021 - 10.1371/journal.pone.0252714
PloS one, Vol. 16 Núm. 6 June (june 2021) , p. e0252714
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
